A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to compare the safety and effectiveness of the study drug
known as LY2944876 to exenatide extended-release and placebo in participants with type 2
diabetes mellitus. All drugs will be given by an injection under the skin. Participants
remain on stable doses of metformin, as prescribed by their personal investigator if they
were on metformin at study entry. Participants' involvement in the study is expected to last
about 30 weeks.